Securities code: 603567 securities abbreviation: Heilongjiang Zbd Pharmaceutical Co.Ltd(603567) Announcement No.: pro 2022-001 Heilongjiang Zbd Pharmaceutical Co.Ltd(603567)
Announcement on resolutions of the 16th meeting of the 4th board of directors
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents.
The 16th meeting of the 4th board of directors of Heilongjiang Zbd Pharmaceutical Co.Ltd(603567) (hereinafter referred to as “the company”) was held by means of communication on December 31, 2021. The notice of the meeting was sent to all directors and other non voting participants by e-mail on December 27, 2021. Five directors should have attended the meeting, and five directors actually attended the meeting. The supervisors and senior managers of the company attended the meeting as nonvoting delegates. The meeting was presided over by Mr. long Tonghua, the director. The convening and convening of the meeting shall comply with the company law of the people’s Republic of China, the articles of association and other relevant provisions. The meeting considered and adopted the following proposals by voting:
1、 The proposal on using raised funds to replace self raised funds invested in raised investment projects in advance was reviewed and adopted
Zhongzhun Certified Public Accountants (special general partnership) reviewed the special instructions on Heilongjiang Zbd Pharmaceutical Co.Ltd(603567) replacement of pre invested funds with raised funds prepared by the company’s management, and issued the special audit report on Heilongjiang Zbd Pharmaceutical Co.Ltd(603567) replacement of raised funds [2021] No. 2276, It is considered that the special description of Heilongjiang Zbd Pharmaceutical Co.Ltd(603567) replacing the funds invested in the project with the raised funds prepared by the management of the company is consistent with the actual situation.
The replacement time of the raised funds is less than 6 months from the arrival time of the raised funds, which meets the requirements of relevant laws and regulations. It is agreed that the company will use the raised funds of RMB 144533694.36 to replace the self raised funds that have been invested in the investment projects with the raised funds in advance.
Voting results: 5 in favor, 0 against and 0 abstention.
For details, please refer to www.sse.com on the website of Shanghai Stock Exchange on the same day com.. cn. Announcement No. 2022-003 disclosed.
2、 The proposal on using some idle raised funds for cash management was reviewed and passed
In order to improve the use efficiency of the company’s idle raised funds, it is agreed to conduct cash management on some idle raised funds with a maximum amount of no more than 450 million yuan (including 450 million yuan) under the premise of ensuring that the normal progress of the company’s raised investment projects and the safety of the raised funds are not affected, so as to purchase investment varieties with high safety, good liquidity and controllable risk, The maximum term of a single financial product shall not exceed one year. Within the above limit, the funds can be used on a rolling basis. Within the limit, the chairman of the company is authorized to exercise the investment decision-making power and sign relevant contract documents within one year from the date of deliberation and approval by the board of directors.
Voting results: 5 in favor, 0 against and 0 abstention.
For details, please refer to www.sse.com on the website of Shanghai Stock Exchange on the same day com.. cn. Announcement No. 2022-004 disclosed.
It is hereby announced.
Heilongjiang Zbd Pharmaceutical Co.Ltd(603567) board of directors January 4, 2022
